Perrigo Co PLC (PRGO)

75.28
NYSE : Health Care
Prev Close 74.65
Day Low/High 74.05 / 75.41
52 Wk Low/High 65.47 / 99.14
Avg Volume 1.85M
Exchange NYSE
Shares Outstanding 143.40M
Market Cap 10.70B
P/E Ratio N/A
Div & Yield 0.64 (0.90%)

Latest News

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Generic drugmakers are likely to limit themselves to acquisitions of small- and mid-sized companies in the immediate future because of over-leveraging and turmoil in the executive ranks..

Valeant's Latest Divestiture Seems to Please Investors But Its Massive Debt Still Hovers

Valeant's Latest Divestiture Seems to Please Investors But Its Massive Debt Still Hovers

Valeant is selling its Australian unit iNova to raise $930 million to pay down debt.

Closing Bell: U.S. Stocks Fall Over Session, Rise for May; Perrigo Bests S&P 500

Closing Bell: U.S. Stocks Fall Over Session, Rise for May; Perrigo Bests S&P 500

Stocks significantly pared losses by the end of the session, though still ended slightly lower.

Perrigo Stock Jumps on 1Q Beat

Perrigo Stock Jumps on 1Q Beat

The quarter's success, Canaccord Genuity analyst Dewey Steadman argued, means Perrigo has removed an overhang.

Market Recon: Watch Core Inflation for a Hint of What the Fed Will Do

Market Recon: Watch Core Inflation for a Hint of What the Fed Will Do

Core CPI has slowed on a year-over-year basis now for three consecutive months.

Perrigo, Taro Show Perils of Failure to Branch in Branded Drugs

Perrigo, Taro Show Perils of Failure to Branch in Branded Drugs

The latest earnings from two of the largest generic drug makers show how important it is for generic firms to have their own stable of higher-margin branded products.

Greenlight Capital Quadrupled General Motors Stake in Activist Push

Greenlight Capital Quadrupled General Motors Stake in Activist Push

David Einhorn is going all-in on General Motors.

Perrigo Announces Two New Independent Directors

New Directors Nominated by Starboard in Accordance With Previously Announced Agreement

Group Stink; Good, the Bad and the Ugly: Doug Kass' Views

Group Stink; Good, the Bad and the Ugly: Doug Kass' Views

Doug Kass shares his thoughts on Facebook, Allergan and Apple.

S&P 500 Lower After Fed Leaves Rates Unchanged, Dow Turns Higher

S&P 500 Lower After Fed Leaves Rates Unchanged, Dow Turns Higher

Stocks hold mostly lower on Wednesday after the Federal Reserve's policy-making group decides to leave its federal funds rate unchanged.

Generics Drop Across Board as DOJ Inquiry Expands

Generics Drop Across Board as DOJ Inquiry Expands

The addition of Perrigo to the list of generics makers under investigation is more bad news for a sector already under pressure from low prices.

SHAREHOLDER ALERT: Goldberg Law PC Announces An Investigation Of Perrigo Company Plc

Goldberg Law PC announces that it is investigating Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO) concerning possible violations of federal securities laws.

PERRIGO INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Perrigo Co. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Perrigo Co.

Perrigo Shares Fall After Disclosing DOJ Investigation

Perrigo Shares Fall After Disclosing DOJ Investigation

The search involves a Department of Justice Antitrust Division investigation in relation to drug pricing in the pharmaceutical industry

Stock Losses Deepen as Oil Tumbles, Apple Falls and Wall Street Awaits the Fed

Stock Losses Deepen as Oil Tumbles, Apple Falls and Wall Street Awaits the Fed

Stock losses deepen on Wednesday morning after crude oil turns negative and a decision from the Federal Reserve looms.

Perrigo Stock Sliding on DOJ Search

Perrigo Stock Sliding on DOJ Search

The investigation is in relation to drug pricing in the pharmaceutical industry.

Perrigo Discloses Investigation

Why Mylan, Perrigo and Endo Won't Be Playing Spoiler in Akorn-Fresenius Tie Up

Why Mylan, Perrigo and Endo Won't Be Playing Spoiler in Akorn-Fresenius Tie Up

Fresenius announced a deal to buy U.S. generic drugmaker Akorn Inc for $4.75 billion, or $34 per share.

Perrigo Announces Restatement Of Previously Issued Forms 10-K And 10-Q Financial Statements; Announces Select Preliminary Unaudited First Quarter 2017 Financial Results

- Tysabri® historical royalty stream determined to be a financial asset; Company to file 2016 Form 10-K, including restated fiscal 2014, fiscal 2015 and transition period 2015 audited financials and certain quarterly financial information as soon as practical